Logo
x

Search

Subscribe Now

hemophilia

Disease of the Month: Hemophilia

Disease of the Month: Hemophilia

  • April 11, 2023
Roche to Present New data of Hemlibra (emicizumab) in P-IIIb STASEY Study for Hemophilia A at ISTH 2021

Roche to Present New data of Hemlibra (emicizumab) in P-IIIb STASEY Study for Hemophilia A at ISTH 2021

  • July 5, 2021
uniQure Signs an Exclusive Research and License Agreement with Gen-X to Develop Novel Synthetic Promoters

uniQure Signs an Exclusive Research and License Agreement with Gen-X to Develop Novel Synthetic Promoters

  • March 3, 2020
Takeda Collaborates with Enzyre to Develop Diagnostic Device to Regulate Coagulation Status in Patients with Hemophilia at Home

Takeda Collaborates with Enzyre to Develop Diagnostic Device to Regulate Coagulation Status in Patients with Hemophilia at Home

  • December 5, 2019
Bayer Collaborates with Children's Hospital of Philadelphia to Develop Oral Non-Replacement Therapy for the Treatment of Hemophilia

Bayer Collaborates with Children's Hospital of Philadelphia to Develop Oral Non-Replacement Therapy for the Treatment of Hemophili...

  • December 5, 2019
Sanofi to Acquire Bioverativ to Treat Hemophilia

Sanofi to Acquire Bioverativ to Treat Hemophilia

  • January 22, 2018
EMA Marketing Authorization of New Drugs in September 2024

    EMA Marketing Authorization of New Drugs in September 2024

    • October 24, 2024
    Pfizer Reports the US FDA’s Approval of Hympavzi to Treat Hemophilia A/B without Inhibitors in Adults and Adolescents

      Pfizer Reports the US FDA’s Approval of Hympavzi to Treat Hemophilia A/B without Inhibitors in Adults and Adolescents

      • October 14, 2024
      Pfizer Reports the CHMP’s Positive Opinion of Hympavzi (Marstacimab) to Treat Hemophilia A and B

        Pfizer Reports the CHMP’s Positive Opinion of Hympavzi (Marstacimab) to Treat Hemophilia A and B

        • September 20, 2024
        Pfizer Reports the EC’s Conditional Approval of Durveqtix (Fidanacogene Elaparvovec) for the Treatment of Hemophilia B

          Pfizer Reports the EC’s Conditional Approval of Durveqtix (Fidanacogene Elaparvovec) for the Treatment of Hemophilia B

          • July 26, 2024
          Pfizer Reports Topline Data from P-III Trial of Giroctocogene Fitelparvovec for Treating Hemophilia A

            Pfizer Reports Topline Data from P-III Trial of Giroctocogene Fitelparvovec for Treating Hemophilia A

            • July 24, 2024
            Sanofi Publishes the P-III (XTEND-Kids) Study Data of Altuviiio to Treat Children with Severe Hemophilia A in the NEJM

              Sanofi Publishes the P-III (XTEND-Kids) Study Data of Altuviiio to Treat Children with Severe Hemophilia A in the NEJM

              • July 18, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.